Calls for Papers from Antibody Therapeutics
Antibody Therapeutics is a peer-reviewed, online, fully open access journal that provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community.
The journal regularly holds calls for papers for upcoming special issues. For the most recent call(s), see below.
Formulation of Antibody-Based Therapeutics
Formulation plays a critical role in the manufacturability and stability of antibody-based therapeutics and has been a topic of intense focus ever since the inception of protein therapeutics. The special issue invites submissions of research and/or review papers on formulation of antibody-based therapeutics.
Guest editors: Yunsong (Frank) Li, PhD, Executive Director, WuXi Biologics and Qingyan Hu, PhD, Associate Director, Regeneron Pharmaceuticals
Manuscript submission deadline: 31 December 2024
Learn more here.
Antibody-Drug Conjugates for Cancer Treatment
Antibody-drug conjugates (ADCs) represent a groundbreaking class of therapies that harness the precision of monoclonal antibodies alongside the potent cytotoxic agents, aiming to mitigate side effects and achieve targeted delivery to tumor cells. This special issue/collection invites submissions of research and/or review papers on various aspects of ADCs.
Guest editors: Victor S. Goldmacher, PhD, Co-founder and CSO of ImmuVia and Chaohong (Mary) Hu, PhD, Co-CEO of Lepu Biopharma Co Ltd, and Founder and CEO of Shanghai Miracogen Inc.
Manuscript submission deadline: 31 December 2024
Learn more here.
Cell Therapies and Cell Engagers against Cancer
In recent years, the field of oncology has witnessed groundbreaking advancements, with immunotherapy emerging as a revolutionary approach. The aim of this collection is to deepen our understanding of these important areas, clarify their mechanisms of action, identify the challenges and opportunities they present, and accelerate the translation of these promising approaches into effective and affordable cancer treatments.
Guest editors: Dr. Baomei Wang, Principal Scientific Researcher, Genentech and Dr. Chengbin Wu, CEO and Founder of EpimAb Biotherapeutics Inc
Manuscript submission deadline: 30 June 2025
Learn more here.
